Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$34.24

-0.37 (-1.07%)

, JNJ

Johnson & Johnson

$133.19

0.3 (0.23%)

06:20
10/06/17
10/06
06:20
10/06/17
06:20

Bayer's Navigate Esus study halted early, had comparable efficacy in arms

Bayer (BAYRY) and its development partner Janssen Research & Development (JNJ) yesterday announced that the Phase III NAVIGATE ESUS study evaluating the efficacy and safety of rivaroxaban -- Xarelto -- for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source has been stopped early. Based on the recommendation by the Independent Data Monitoring Committee following a planned interim analysis, the trial was halted early as it showed comparable efficacy between the rivaroxaban and aspirin arms and very little chance of showing overall benefit if the study were completed. While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm. The decision to halt the trial was taken jointly by the Academic Leadership of the trial and the sponsor Bayer. The Phase III NAVIGATE ESUS study has enrolled 7,214 patients from 459 sites across 31 countries worldwide. In the study, patients were randomized to receive either rivaroxaban 15 mg once daily or aspirin 100 mg once daily alone. The primary efficacy endpoint was a composite of stroke and systemic embolism. The primary safety endpoint was major bleeding according to the criteria of the International Society on Thrombosis and Haemostasis. A complete data analysis is expected to be presented at an upcoming medical meeting in 2018.

BAYRY

Bayer

$34.24

-0.37 (-1.07%)

JNJ

Johnson & Johnson

$133.19

0.3 (0.23%)

  • 08

    Oct

  • 17

    Oct

  • 23

    Oct

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

BAYRY Bayer
$34.24

-0.37 (-1.07%)

08/18/17
UBSW
08/18/17
DOWNGRADE
Target $128
UBSW
Neutral
Monsanto downgraded to Neutral from Buy at UBS
UBS analyst John Roberts downgraded Monsanto (MON) to Neutral saying the shares are now less than 10% away from the accepted Bayer (BAYRY) offer of $128. The analyst calculates that the market is currently pricing in a 70% chance of the deal going through. His view that the deal could be approved remains unchanged. Approvals of peer deals suggest antitrust approval likely for Monsanto, Roberts tells investors in a research note. The analyst keeps a $128 price target for Monsanto shares.
09/05/17
BERN
09/05/17
NO CHANGE
BERN
Bernstein still sees 'very high' probability of Bayer, Monsanto deal approval
Bernstein analyst Jeremy Redenius notes that the European Commission has opened an in-depth review of the Bayer (BAYRY)/Monsanto (MON) deal due to concerns of reduced competition in pesticides, seeds, and traits. The analyst believes this is not surprising, as the in-depth review is the norm for deals of this size. Comparing the EC's initial concerns with those of the Dow/DuPont (DWDP) deal, he still sees a "very high" probability of deal approval.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.
10/03/17
RHCO
10/03/17
NO CHANGE
RHCO
TG Therapeutics has positive read through from Bayer approval, says SunTrust
SunTrust analyst Yatin Suneja believes that the FDA's decision to grant accelerated approval to Bayer's (BAYRY) Aliqopa, a PI3K-delta inhibitor, as a treatment for Relapsed/Refractory Follicular Lymphoma, bodes well for TG Therapeutics' (TGTX) own PI3K-delta inhibitor, TGR-120. The analyst says that the lack of a black box warning on Bayer's Aliqopa shows that not all PI3K-delta inhibitors have the safety issues that have been attributed to them in the past. Suneja says that "Aliqopa's approval reflects positively on TGR-1202, which offers best-in-class safety , and provides clarity on TGR-1202's regulatory pathway in" lymphoma The analyst says that investors are "overlooking" its potential in " lymphoma, and keeps a Buy rating on the shares.
JNJ Johnson & Johnson
$133.19

0.3 (0.23%)

09/25/17
09/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) initiated with a Neutral at Citi. 2. CoreSite Realty (COR) initiated with a Neutral at JPMorgan. 3. Hi-Crush Partners (HCLP) initiated with an Overweight at Piper Jaffray. 4. Zillow (Z, ZG) initiated with a Neutral at Macquarie. 5. Big Lots (BIG) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/17
SBSH
10/03/17
NO CHANGE
SBSH
Citi's general surgery survey 'very positive' for Intuitive Surgical
Citi analyst Amit Hazan says his firm's general surgery survey is "very positive" for Intuitive Surgical (ISRG), and "much less so" for Medtronic (MDT) and Johnson & Johnson (JNJ). Robotic procedures are expected to be up about 30% this year and next, with ventral hernia leading, Hazan tells investors in a research note partially titled "It's a Good Time to be a Robot." He believes robotic is really starting to hurt laparoscopy and that Medtronic and J&J will likely be forced to talk about the headwind publicly.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.

TODAY'S FREE FLY STORIES

TXN

Texas Instruments

$95.18

1.73 (1.85%)

13:10
10/23/17
10/23
13:10
10/23/17
13:10
Options
Texas Instruments calls active as shares see relative strength ahead of earnings »

Texas Instruments calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

EEFT

Euronet

$98.71

1.93 (1.99%)

13:09
10/23/17
10/23
13:09
10/23/17
13:09
Conference/Events
Euronet management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 14

    Dec

NVS

Novartis

$86.19

0.45 (0.52%)

, MCD

McDonald's

$164.22

-2.08 (-1.25%)

13:06
10/23/17
10/23
13:06
10/23/17
13:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$86.19

0.45 (0.52%)

MCD

McDonald's

$164.22

-2.08 (-1.25%)

MMM

3M

$222.12

0.8 (0.36%)

UTX

United Technologies

$120.63

-0.3 (-0.25%)

LLY

Eli Lilly

$87.68

0.45 (0.52%)

LMT

Lockheed Martin

$320.44

0.44 (0.14%)

CAT

Caterpillar

$132.06

0.7 (0.53%)

BIIB

Biogen

$338.10

-4.32 (-1.26%)

GM

General Motors

$45.37

-0.2389 (-0.52%)

SHW

Sherwin-Williams

$389.65

-0.055 (-0.01%)

INFY

Infosys

$14.90

0.34 (2.34%)

GLW

Corning

$30.36

0.295 (0.98%)

PCAR

Paccar

$74.92

1.15 (1.56%)

SWK

Stanley Black & Decker

$159.75

-0.37 (-0.23%)

FITB

Fifth Third

$28.60

0.32 (1.13%)

CNC

Centene

$97.59

1.09 (1.13%)

WAT

Waters

$188.63

0.49 (0.26%)

IPG

Interpublic Group

$20.62

-0.2641 (-1.26%)

WAB

Wabtec

$76.28

-0.59 (-0.77%)

HUBB

Hubbell

$121.43

-1.6355 (-1.33%)

JBLU

JetBlue

$20.35

0.01 (0.05%)

PII

Polaris Industries

$106.55

0.09 (0.08%)

GPK

Graphic Packaging

$14.30

0.02 (0.14%)

R

Ryder

$82.98

-0.67 (-0.80%)

CVLT

Commvault

$58.55

0.5 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 07

    Dec

  • 17

    May

WHR

Whirlpool

$182.85

0.39 (0.21%)

, ARNC

Arconic

$25.05

-2.12 (-7.80%)

13:05
10/23/17
10/23
13:05
10/23/17
13:05
Earnings
Notable companies reporting after market close »

Notable companies…

WHR

Whirlpool

$182.85

0.39 (0.21%)

ARNC

Arconic

$25.05

-2.12 (-7.80%)

ZION

Zions Bancorp

$46.76

0.71 (1.54%)

CR

Crane

$84.02

-0.09 (-0.11%)

OI

Owens-Illinois

$25.35

-0.24 (-0.94%)

RMBS

Rambus

$13.70

0.12 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 14

    Nov

  • 07

    Dec

COG

Cabot Oil & Gas

$25.39

-0.14 (-0.55%)

13:05
10/23/17
10/23
13:05
10/23/17
13:05
Options
Cabot Oil & Gas call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

13:05
10/23/17
10/23
13:05
10/23/17
13:05
General news
Treasury Action: the markets are quiet as a wait and see stance prevails »

Treasury Action: the…

NKE

Nike

$53.79

0.73 (1.38%)

12:55
10/23/17
10/23
12:55
10/23/17
12:55
Options
Nike put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ADP

ADP

$115.93

1.31 (1.14%)

12:54
10/23/17
10/23
12:54
10/23/17
12:54
Hot Stocks
ADP 'strongly disagrees' with Glass Lewis' recommendation on director election »

ADP issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

UTX

United Technologies

$120.73

-0.205 (-0.17%)

12:46
10/23/17
10/23
12:46
10/23/17
12:46
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend ahead of news »

Shares have been trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FCX

Freeport McMoRan

$14.78

-0.049 (-0.33%)

12:45
10/23/17
10/23
12:45
10/23/17
12:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AGN

Allergan

$189.61

1.33 (0.71%)

12:45
10/23/17
10/23
12:45
10/23/17
12:45
Periodicals
Allergan has weak balance sheet after large buybacks, WSJ's Grant says »

Allergan squandered the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 01

    Nov

  • 06

    Nov

SSYS

Stratasys

$23.21

2.26 (10.79%)

12:37
10/23/17
10/23
12:37
10/23/17
12:37
Hot Stocks
Stratasys announces NYU study on treating kidney issues with 3D technology »

Stratasys announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

TAL

TAL Education

$34.05

-0.865 (-2.48%)

12:35
10/23/17
10/23
12:35
10/23/17
12:35
Options
Tal Education Group put volume heavy and directionally bearish »

Bearish flow noted in Tal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

LGL

LGL Group

$5.66

0.1 (1.80%)

12:32
10/23/17
10/23
12:32
10/23/17
12:32
Hot Stocks
LGL Group reports extension of rights offering expiration to November 13 »

The LGL Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBW

Build-A-Bear

$8.15

-0.1 (-1.21%)

12:32
10/23/17
10/23
12:32
10/23/17
12:32
Conference/Events
Build-A-Bear management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

SYBX

Synlogic

$15.01

-1.46 (-8.86%)

12:28
10/23/17
10/23
12:28
10/23/17
12:28
Conference/Events
Synlogic management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ROIC

Retail Opportunity

$18.76

-0.3 (-1.57%)

12:26
10/23/17
10/23
12:26
10/23/17
12:26
Conference/Events
Retail Opportunity management to meet with Jefferies »

Meetings to be held n…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

MCD

McDonald's

$164.42

-1.88 (-1.13%)

12:26
10/23/17
10/23
12:26
10/23/17
12:26
Technical Analysis
Technical Earnings Preview: McDonald's testing support ahead of earnings »

Price has been within a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

XOM

Exxon Mobil

$83.21

0.1 (0.12%)

12:20
10/23/17
10/23
12:20
10/23/17
12:20
Options
11.7K Exxon Mobile Jan 82.5 - Mar 87.5 call spreads bought for $1.40 »

11.7K Exxon Mobile Jan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

$NSD

NASDAQ Market Internals

12:17
10/23/17
10/23
12:17
10/23/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
10/23/17
10/23
12:16
10/23/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
10/23/17
10/23
12:15
10/23/17
12:15
General news
Treasury Option Action: some "call fly" demand »

Treasury Option Action:…

SAGE

Sage Therapeutics

$63.50

0.58 (0.92%)

12:10
10/23/17
10/23
12:10
10/23/17
12:10
Options
Sizable ratio spread in Sage Therapeutics »

Sizable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$35.00

-0.25 (-0.71%)

12:08
10/23/17
10/23
12:08
10/23/17
12:08
Periodicals
Volkswagen receives approval from U.S regulators for SUV fix, Reuters says »

U.S and California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBS

Rambus

$13.70

0.12 (0.88%)

12:05
10/23/17
10/23
12:05
10/23/17
12:05
Technical Analysis
Technical Earnings Preview: Rambus in bullish price channel ahead of news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.